Le Lézard19 分钟
Cantargia Reports Promising CAN10 Phase 1 Data From First Multiple Dose Cohort, and FDA and ...
Promising multiple dose PK data continue to support 4-weekly dosingFDA advice received supporting phase 2 design in HSStrong Key Opinion Leader (KOL) support for CAN10 in ...